Re: Erdafitinib in BCG-treated High-risk Non-muscleinvasive Bladder Cancer

被引：0
|
作者：
Duquesne, Igor [1 ]
de la Taille, Alexandre [1 ]
机构：
[1] Univ Paris Est Creteil, Henri Mondor Hosp, Dept Urol, Creteil, France
来源：
EUROPEAN UROLOGY | 2024年 / 85卷 / 01期
关键词：
PEMBROLIZUMAB;
D O I：
10.1016/j.eururo.2024.02.021
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：74 / 75
页数：2
相关论文
共 50 条
  • [1] Re: Erdafitinib in BCG-treated High-risk Non-muscle- invasive Bladder Cancer
    Babjuk, Marko
    EUROPEAN UROLOGY, 2024, 86 (03) : 280 - 280
  • [2] Re: Erdafitinib in BCG-Treated High-Risk Non-Muscle-Invasive Bladder Cancer
    Catto, J. W. F.
    Tran, B.
    Roupret, M.
    JOURNAL OF UROLOGY, 2024, 212 (05): : 779 - 779
  • [3] Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
    Catto, J. W. F.
    Tran, B.
    Roupret, M.
    Gschwend, J. E.
    Loriot, Y.
    Nishiyama, H.
    Redorta, J. P.
    Daneshmand, S.
    Hussain, S. A.
    Cutuli, H. J.
    Procopio, G.
    Guadalupi, V.
    Vasdev, N.
    Naini, V.
    Crow, L.
    Triantos, S.
    Baig, M.
    Steinberg, G.
    ANNALS OF ONCOLOGY, 2024, 35 (01) : 98 - 106
  • [4] Interest of next-generation sequencing in BCG-treated high-risk bladder cancer
    Jungels, C.
    Chanza, N. Martinez
    Albisinni, S.
    Mercier, M.
    d'Haene, N.
    Rorive, S.
    Roumeguere, T.
    PROGRES EN UROLOGIE, 2018, 28 (06): : 344 - 350
  • [5] Comparison of two ICI-based microtubule antagonist therapies for high-risk, non-muscleinvasive bladder cancer
    Niu, Yuanjie
    Hu, Hailong
    Li, Hong Zheng
    Shen, Chong
    An, Zesheng
    Wu, Zhouliang
    Zhang, Zhe
    Huang, Shiwang
    Zhao, Gangjian
    Guo, Shizheng
    Chen, Houyuan
    Jia, Kaipeng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Adding Mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscleinvasive -bladder cancer: A randomised phase 3 trial: The BCG plus MM Study (ANZUP1301)
    Hayne, D.
    Stockler, M.
    Martin, A. J.
    Mccombie, S.
    Zebic, D.
    Krieger, L.
    Anderson, P.
    Bastick, P.
    Beardsley, E.
    Blatt, A.
    Frydenberg, M.
    Green, W.
    Grummet, J.
    Hawks, C.
    Ischia, J.
    Mitterdorfer, A.
    Patel, M.
    Roberts, M.
    Sengupta, S.
    Srivastav, R.
    Winter, M.
    Redfern, A. D.
    Davis, I. D.
    EUROPEAN UROLOGY, 2023, 83 : S746 - S747
  • [7] Impact of risk factors on oncologic outcomes in intermediate-risk non-muscleinvasive bladder cancer
    Laukhtina, E.
    Klemm, J.
    Fazekas, T.
    Matsukawa, A.
    Gontero, P.
    Soria, F.
    Babjuk, M.
    Teoh, J. Y-C.
    Moschini, M.
    Karakiewicz, P. I.
    Abufaraj, M.
    Comperat, E.
    Shariat, S. F.
    EUROPEAN UROLOGY, 2024, 85 : S1709 - S1710
  • [8] HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY OR OTHER SUBTYPES NOT A PREDICTOR FOR PROGRESSION IN BCG-TREATED PATIENTS
    Craig, Calkins Daniel
    Facundo, Davaro
    Chris, Guske
    Richard, Sirard, III
    Roger, Li
    Scott, Gilbert
    Wade, Sexton
    Philippe E, Spiess
    Michael, Poch
    Alice, Yu
    Logan, Zemp
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S52 - S52
  • [9] Pembrolizumab monotherapy for high-risk non-muscleinvasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial
    Necchi, Andrea
    Roumiguie, Mathieu
    Kamat, Ashish M.
    Shore, Neal D.
    Boormans, Joost L.
    Esen, Ahmet Adil
    Lebret, Thierry
    Kandori, Shuya
    Bajorin, Dean F.
    Krieger, Laurence E. M.
    Niglio, Scot A.
    Uchio, Edward M.
    Seo, Ho Kyung
    de Wit, Ronald
    Singer, Eric A.
    Grivas, Petros
    Nishiyama, Hiroyuki
    Li, Haojie
    Baranwal, Pranshu
    van den Sigtenhorst-fijlstra, Margot
    Kapadia, Ekta
    Kulkarni, Girish S.
    LANCET ONCOLOGY, 2024, 25 (06): : 720 - 730
  • [10] BLADDER CANCER Validating the EORTC risk tables in BCG-treated patients
    Buethe, David D.
    Sexton, Wade J.
    NATURE REVIEWS UROLOGY, 2011, 8 (09) : 480 - 481
12345